An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available be

Question

Six frontier AI models put this at 14% by 22 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

14% — the median of 6 frontier models, resolving by 2036-10-22.

Answer

Gemini (Google): 18% — Halting or reversing neurodegeneration requires repairing lost synapses, which no drug currently in Phase II/III demonstrates. A 10-year horizon leaves time only for drugs already in Phase I/II, where candidates show at best 25-35% slowing, not arrest. FDA requires robust cognitive endpoints like ADAS-Cog; demonstrating zero decline or reversal necessitates 18-24 month Phase III trials. A successful trial would likely need to hit non-amyloid targets like tau or neuroinflammation, where Phase II attrition exceeds 85%.

Answer

Claude (Anthropic): 10% — Requires a drug that reverses, not just slows, decline—no current candidate in late trials shows this. Lecanemab/donanemab only modestly slow decline ~27-35%, far from halting or reversing cognition, after decades of amyloid-hypothesis drugs underdelivering. A true disease-reversing therapy would need novel mechanism (tau clearance, neuroregeneration, combination therapy) still in early/mid trials as of 2026, leaving under a… Base rate for any single neurodegenerative breakthrough achieving full approval within a 10-year window is low; most pipeline progress is incremental, though…

Answer

GPT (OpenAI): 28% — It hinges on whether a disease-modifying approach can show durable cognitive benefit beyond amyloid’s modest slowing. FDA would need a pivotal program with sustained arrest or improvement on validated cognition measures and acceptable safety by roughly 2034. No Alzheimer’s therapy has yet reversed decline; lecanemab and donanemab established modest slowing, making a decade-long leap possible but below base-rate likely. A replicated phase 2 signal of sustained cognitive improvement from tau, metabolic, immune, or combination therapy by 2029 would sharply raise the odds.

Answer

Grok (xAI): 18% — No late-stage candidate has shown arrest/reversal; 10y window still requires a new mechanism to succeed in Ph3+FDA. Amyloid mAbs (lecanemab/donanemab) only slow ~30%; tau/TREM2/ASO programs remain Ph1-2 with high historic AD Ph3 failure (~90%). A 2027-28 Ph3 start could finish by 2032-34 then 1y review, but none now meet the halt/reverse bar even in early data. Reversal would most shift if a 2027 readout (e.g., anti-tau or gene therapy) shows CDR-SB improvement, not just slowing.

Answer

DeepSeek (DeepSeek): 9% — Whether a disease-modifying Alzheimer's drug clears Phase 3 with cognitive arrest or reversal, not just slowing, by 2036. Lecanemab and donanemab were approved in 2023-2024 but only slow decline ~27-35% on CDR-SB; no approved agent has halted or reversed decline. Anti-amyloid antibodies targeting plaque removal have repeatedly failed to produce reversal; the field's next bets are tau, anti-inflammatory, and GLP-1 agents, most… A single positive Phase 3 with a reversal endpoint (e.g., improved ADAS-Cog) would change this overnight, but the 10-year window allows roughly one more full…

Answer

Qwen (Alibaba): 9% — No mechanism in late-stage development is positioned to demonstrate full arrest or reversal of cognitive decline within a decade. Every Phase 3 AD trial to date has shown at best ~30% slowing; halting requires a qualitatively different effect size no pipeline candidate is powered to detect. Combination or multi-target strategies that might approach halting are still in Phase 1/2, meaning even optimistic timelines put approval no earlier than 2032-2033 with… A surprise positive Phase 3 readout from an anti-tau or neuroimmune agent in 2027-2028 showing near-complete stabilization would be the development most likely to raise…

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

What each one said

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.

A universal cure or definitive therapeutic regimen eliminating all major human cancers is approved by a major regulatory agency before 2050.